Biogenic Nanosilver against Multidrug-Resistant Bacteria (MDRB)
AbstractMultidrug-resistant bacteria (MDRB) are extremely dangerous and bring a serious threat to health care systems as they can survive an attack from almost any drug. The bacteria’s adaptive way of living with the use of antimicrobials and antibiotics caused them to modify and prevail in hostile conditions by creating resistance to known antibiotics or their combinations. The emergence of nanomaterials as new antimicrobials introduces a new paradigm for antibiotic use in various fields. For example, silver nanoparticles (AgNPs) are the oldest nanomaterial used for bactericide and bacteriostatic purposes. However, for just a few decades these have been produced in a biogenic or bio-based fashion. This review brings the latest reports on biogenic AgNPs in the combat against MDRB. Some antimicrobial mechanisms and possible silver resistance traits acquired by bacteria are also presented. Hopefully, novel AgNPs-containing products might be designed against MDR bacterial infections. View Full-Text
Share & Cite This Article
Barros, C.H.N.; Fulaz, S.; Stanisic, D.; Tasic, L. Biogenic Nanosilver against Multidrug-Resistant Bacteria (MDRB). Antibiotics 2018, 7, 69.
Barros CHN, Fulaz S, Stanisic D, Tasic L. Biogenic Nanosilver against Multidrug-Resistant Bacteria (MDRB). Antibiotics. 2018; 7(3):69.Chicago/Turabian Style
Barros, Caio H.N.; Fulaz, Stephanie; Stanisic, Danijela; Tasic, Ljubica. 2018. "Biogenic Nanosilver against Multidrug-Resistant Bacteria (MDRB)." Antibiotics 7, no. 3: 69.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.